Catecholamine-induced alterations in glucose homeostasis in baboons, dogs, rabbits, and rats

Comparative effects of somatostatin

Lee C. Woodson, David E. Potter

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

A considerable amount of species variation exists in the relative hyperglycemic activities of catecholamines. For example, epinephrine (EPI) is a potent hyperglycemic agent in all mammalian species, whereas isoproterenol (ISO) has strong hyperglycemic activity in dogs, moderate activity in baboons, weak activity in rabbits, and relative inactivity in normal fed rats.1.2 Moreover, in rabbits there are differences between the in vitro glucose mobilizing activities of catecholamines as compared to in vivo effects.3 This suggests that there may be important indirect determinants of hyperglycemic activity that account for the species variation in the relative hyperglycemic activities of catecholamines. Previous work from our laboratory has shown that the hyperglycemic effect of ISO in rats is limited by its stimulating effect on insulin release.4 On the basis of indirect evidence, Sokal and Sarcione5 suggested that the hyperglycemia produced by EPI is mediated through increased glucagon release. Since catecholamines have been shown to release the potent glycogenolytic and gluconeogenic hormone, glucagon,6 it seems appropriate to examine the involvement of glucagon as well as insulin in the production of hyperglycemia by catecholamines in a variety of laboratory animals. We have hypothesized that pancreatic hormone release is an important determinant of catecholamine-induced hyperglycemia, and different patterns of pancreatic hormone release may explain, in part, the differences in the relative hyperglycemic activities of catecholamines that occur within and between species.

Original languageEnglish (US)
Pages (from-to)1441-1444
Number of pages4
JournalMetabolism
Volume27
Issue number9 SUPPL. 1
DOIs
StatePublished - 1978

Fingerprint

Papio
Somatostatin
Catecholamines
Homeostasis
Dogs
Rabbits
Glucose
Glucagon
Pancreatic Hormones
Hyperglycemia
Isoproterenol
Epinephrine
Insulin
Laboratory Animals
Hormones

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Catecholamine-induced alterations in glucose homeostasis in baboons, dogs, rabbits, and rats : Comparative effects of somatostatin. / Woodson, Lee C.; Potter, David E.

In: Metabolism, Vol. 27, No. 9 SUPPL. 1, 1978, p. 1441-1444.

Research output: Contribution to journalArticle

@article{cb1b0677262a499aa2687a7b5e4b4abb,
title = "Catecholamine-induced alterations in glucose homeostasis in baboons, dogs, rabbits, and rats: Comparative effects of somatostatin",
abstract = "A considerable amount of species variation exists in the relative hyperglycemic activities of catecholamines. For example, epinephrine (EPI) is a potent hyperglycemic agent in all mammalian species, whereas isoproterenol (ISO) has strong hyperglycemic activity in dogs, moderate activity in baboons, weak activity in rabbits, and relative inactivity in normal fed rats.1.2 Moreover, in rabbits there are differences between the in vitro glucose mobilizing activities of catecholamines as compared to in vivo effects.3 This suggests that there may be important indirect determinants of hyperglycemic activity that account for the species variation in the relative hyperglycemic activities of catecholamines. Previous work from our laboratory has shown that the hyperglycemic effect of ISO in rats is limited by its stimulating effect on insulin release.4 On the basis of indirect evidence, Sokal and Sarcione5 suggested that the hyperglycemia produced by EPI is mediated through increased glucagon release. Since catecholamines have been shown to release the potent glycogenolytic and gluconeogenic hormone, glucagon,6 it seems appropriate to examine the involvement of glucagon as well as insulin in the production of hyperglycemia by catecholamines in a variety of laboratory animals. We have hypothesized that pancreatic hormone release is an important determinant of catecholamine-induced hyperglycemia, and different patterns of pancreatic hormone release may explain, in part, the differences in the relative hyperglycemic activities of catecholamines that occur within and between species.",
author = "Woodson, {Lee C.} and Potter, {David E.}",
year = "1978",
doi = "10.1016/0026-0495(78)90089-6",
language = "English (US)",
volume = "27",
pages = "1441--1444",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "9 SUPPL. 1",

}

TY - JOUR

T1 - Catecholamine-induced alterations in glucose homeostasis in baboons, dogs, rabbits, and rats

T2 - Comparative effects of somatostatin

AU - Woodson, Lee C.

AU - Potter, David E.

PY - 1978

Y1 - 1978

N2 - A considerable amount of species variation exists in the relative hyperglycemic activities of catecholamines. For example, epinephrine (EPI) is a potent hyperglycemic agent in all mammalian species, whereas isoproterenol (ISO) has strong hyperglycemic activity in dogs, moderate activity in baboons, weak activity in rabbits, and relative inactivity in normal fed rats.1.2 Moreover, in rabbits there are differences between the in vitro glucose mobilizing activities of catecholamines as compared to in vivo effects.3 This suggests that there may be important indirect determinants of hyperglycemic activity that account for the species variation in the relative hyperglycemic activities of catecholamines. Previous work from our laboratory has shown that the hyperglycemic effect of ISO in rats is limited by its stimulating effect on insulin release.4 On the basis of indirect evidence, Sokal and Sarcione5 suggested that the hyperglycemia produced by EPI is mediated through increased glucagon release. Since catecholamines have been shown to release the potent glycogenolytic and gluconeogenic hormone, glucagon,6 it seems appropriate to examine the involvement of glucagon as well as insulin in the production of hyperglycemia by catecholamines in a variety of laboratory animals. We have hypothesized that pancreatic hormone release is an important determinant of catecholamine-induced hyperglycemia, and different patterns of pancreatic hormone release may explain, in part, the differences in the relative hyperglycemic activities of catecholamines that occur within and between species.

AB - A considerable amount of species variation exists in the relative hyperglycemic activities of catecholamines. For example, epinephrine (EPI) is a potent hyperglycemic agent in all mammalian species, whereas isoproterenol (ISO) has strong hyperglycemic activity in dogs, moderate activity in baboons, weak activity in rabbits, and relative inactivity in normal fed rats.1.2 Moreover, in rabbits there are differences between the in vitro glucose mobilizing activities of catecholamines as compared to in vivo effects.3 This suggests that there may be important indirect determinants of hyperglycemic activity that account for the species variation in the relative hyperglycemic activities of catecholamines. Previous work from our laboratory has shown that the hyperglycemic effect of ISO in rats is limited by its stimulating effect on insulin release.4 On the basis of indirect evidence, Sokal and Sarcione5 suggested that the hyperglycemia produced by EPI is mediated through increased glucagon release. Since catecholamines have been shown to release the potent glycogenolytic and gluconeogenic hormone, glucagon,6 it seems appropriate to examine the involvement of glucagon as well as insulin in the production of hyperglycemia by catecholamines in a variety of laboratory animals. We have hypothesized that pancreatic hormone release is an important determinant of catecholamine-induced hyperglycemia, and different patterns of pancreatic hormone release may explain, in part, the differences in the relative hyperglycemic activities of catecholamines that occur within and between species.

UR - http://www.scopus.com/inward/record.url?scp=0018086890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018086890&partnerID=8YFLogxK

U2 - 10.1016/0026-0495(78)90089-6

DO - 10.1016/0026-0495(78)90089-6

M3 - Article

VL - 27

SP - 1441

EP - 1444

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 9 SUPPL. 1

ER -